Free Trial

Vera Therapeutics, Inc. (NASDAQ:VERA) Receives $63.33 Consensus Price Target from Analysts

Vera Therapeutics logo with Medical background

Shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) have been given a consensus recommendation of "Buy" by the ten research firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $63.33.

VERA has been the subject of several analyst reports. HC Wainwright initiated coverage on shares of Vera Therapeutics in a report on Monday, May 5th. They issued a "buy" rating and a $75.00 target price for the company. JPMorgan Chase & Co. lowered their target price on shares of Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating for the company in a report on Tuesday, March 4th. Wolfe Research initiated coverage on shares of Vera Therapeutics in a report on Tuesday, February 4th. They issued an "outperform" rating and a $49.00 target price for the company. Wedbush lowered their target price on shares of Vera Therapeutics from $34.00 to $26.00 and set a "neutral" rating for the company in a report on Wednesday, May 7th. Finally, Guggenheim increased their target price on shares of Vera Therapeutics from $59.00 to $61.00 and gave the company a "buy" rating in a report on Thursday, February 27th.

Check Out Our Latest Report on Vera Therapeutics

Hedge Funds Weigh In On Vera Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Avoro Capital Advisors LLC boosted its position in Vera Therapeutics by 30.2% during the fourth quarter. Avoro Capital Advisors LLC now owns 5,610,000 shares of the company's stock worth $237,247,000 after purchasing an additional 1,300,410 shares during the period. Price T Rowe Associates Inc. MD boosted its position in shares of Vera Therapeutics by 8.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 4,754,832 shares of the company's stock valued at $114,212,000 after acquiring an additional 377,783 shares during the period. FMR LLC boosted its position in shares of Vera Therapeutics by 9.6% in the fourth quarter. FMR LLC now owns 3,053,126 shares of the company's stock valued at $129,117,000 after acquiring an additional 267,842 shares during the period. Vanguard Group Inc. boosted its position in shares of Vera Therapeutics by 14.3% in the fourth quarter. Vanguard Group Inc. now owns 2,949,564 shares of the company's stock valued at $124,737,000 after acquiring an additional 369,387 shares during the period. Finally, Vestal Point Capital LP boosted its position in shares of Vera Therapeutics by 132.6% in the first quarter. Vestal Point Capital LP now owns 2,500,000 shares of the company's stock valued at $60,050,000 after acquiring an additional 1,425,000 shares during the period. Institutional investors own 99.21% of the company's stock.

Vera Therapeutics Stock Up 6.8%

Shares of VERA stock traded up $1.29 on Monday, hitting $20.16. The stock had a trading volume of 1,189,942 shares, compared to its average volume of 787,519. The business has a 50 day moving average of $22.25 and a 200 day moving average of $32.60. The stock has a market cap of $1.29 billion, a price-to-earnings ratio of -7.72 and a beta of 1.28. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76. Vera Therapeutics has a 12-month low of $18.53 and a 12-month high of $51.61.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). During the same quarter in the prior year, the firm posted ($0.56) EPS. As a group, analysts expect that Vera Therapeutics will post -2.89 EPS for the current year.

About Vera Therapeutics

(Get Free Report

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.

Recommended Stories

Analyst Recommendations for Vera Therapeutics (NASDAQ:VERA)

Should You Invest $1,000 in Vera Therapeutics Right Now?

Before you consider Vera Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vera Therapeutics wasn't on the list.

While Vera Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines